Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
Autor: | Robert Lowsky, Paolo A. Muraro, Richard A. Nash, Laura E. Baldassari, Stefanie Sarantopoulos, Mark S. Freedman, James Bowen, Marcelo C. Pasquini, Paul A. Carpenter, Keith M. Sullivan, Christopher Bredeson, Jan Storek, Bipin N. Savani, John R. Corboy, Linda M. Griffith, Harold L. Atkins, Jeffrey A. Cohen, George E. Georges, Navneet S. Majhail |
---|---|
Přispěvatelé: | National Institutes of Health |
Rok vydání: | 2019 |
Předmět: |
Canada
medicine.medical_specialty Coverage medicine.medical_treatment Immunology indication Salvage therapy IMMUNOABLATION PROGRESSION Stem cells Hematopoietic stem cell transplantation multiple sclerosis Transplantation Autologous ECTRIMS/EAN GUIDELINE 03 medical and health sciences 0302 clinical medicine LONG-TERM OUTCOMES Autologous hematopoietic cell transplantation PEOPLE Humans Medicine Intensive care medicine Adverse effect Societies Medical Patient Care Team Salvage Therapy Transplantation Science & Technology business.industry DISABILITY Multiple sclerosis Hematopoietic Stem Cell Transplantation 1103 Clinical Sciences Retrospective cohort study ADULTS Hematology medicine.disease United States Clinical trial Treatment Outcome Systematic review 030220 oncology & carcinogenesis DISEASE-MODIFYING THERAPIES DOSE IMMUNOSUPPRESSIVE THERAPY business Life Sciences & Biomedicine PHARMACOLOGICAL-TREATMENT 030215 immunology |
Zdroj: | Biology of Blood and Marrow Transplantation. 25:845-854 |
ISSN: | 1083-8791 |
Popis: | Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. The use of immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need. On behalf of the American Society for Blood and Bone Marrow Transplantation (ASBMT), a panel of experts in AHCT and MS convened to review available evidence and make recommendations on MS as an indication for AHCT. A review of recent literature identified 8 retrospective studies, 8 clinical trials, and 3 meta-analyses/systematic reviews. In aggregate, these studies indicate that AHCT is an efficacious and safe treatment for active relapsing forms of MS to prevent clinical relapse, magnetic resonance imaging-detectable lesion activity, and worsening disability and to reverse disability without unexpected adverse events. Based on the available evidence, the ASBMT recommends that treatment-refractory relapsing MS with high risk of future disability be considered a "standard of care, clinical evidence available" indication for AHCT. Collaboration of neurologists with expertise in treating MS and transplantation physicians with experience performing AHCT for autoimmune disease is crucial for ensuring appropriate patient selection and optimizing transplantation procedures to improve patient outcomes. Transplantation centers in the United States and Canada are strongly encouraged to report baseline and outcomes data on patients receiving AHCT for multiple sclerosis to the Center for International Blood and Marrow Transplant Research. |
Databáze: | OpenAIRE |
Externí odkaz: |